A 28-amino-acid thymic peptide studied for T-cell maturation, innate immune tone, and host-defense immunology.
Pre-loaded with a typical Thymosin Alpha-1 vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for Thymosin Alpha-1. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 1.6 mg – 3.2 mg | twice weekly | subcutaneous | Commonly cited thymalfasin / Tα1 research and clinical-literature exposure 1.6 mg SC twice weekly is among the most frequently referenced schedules in thymalfasin literature; higher or alternate schedules appear in some protocols. |
| 900 mcg – 1.6 mg | two to seven times weekly depending on protocol | subcutaneous | Alternate research schedules summarized in reviews Published regimens vary by indication model and study era; there is no single universal research dose. |
People searching this page also look for: thymosin alpha 1 peptide dosage, thymosin peptide dosage, thymosin alpha 1 peptide dosage protocol.
Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from thymic tissue and later produced synthetically. It has been investigated for decades as an immunomodulatory molecule that can influence T-cell maturation, dendritic-cell function, and innate immune signaling. In some countries a pharmaceutical form (thymalfasin) has been used clinically; that regulated product context is separate from bulk research-grade peptide supply.
The research literature spans viral immunology, sepsis adjunct models, vaccine-response biology, and cancer-immune interaction studies. Reviews summarize a large cumulative clinical-trial footprint and generally describe a favorable tolerability profile in studied settings, while also noting heterogeneity of indications and study quality.
Research-grade thymosin alpha-1 is Research Use Only. It is not an FDA-approved U.S. drug product for general therapeutic marketing in this RUO context, and it is not for human consumption. Dosage figures below are literature references for education only.
Tα1 interacts with innate immune pattern-recognition pathways, including Toll-like receptor-related signaling in dendritic cells and other antigen-presenting cells. Downstream effects reported in the literature include enhanced T-cell differentiation and function, modulation of cytokine patterns, support of NK-cell activity, and context-dependent restoration of immune competence in suppressed states. It is better described as a multi-node immune modulator than as a single-receptor hormone mimetic.
T-cell and dendritic-cell immunology · host defense and viral immunology · sepsis and critical-illness immune tone · vaccine adjuvant biology · cancer-immune interaction models
Immunologists, infectious-disease researchers, and translational oncology groups are the primary audience. Additional work appears in aging-immunity and vaccine-response laboratories interested in thymic peptide biology.
Keep lyophilized Tα1 cold, dry, and light-protected. After reconstitution, refrigerate and handle as a labile peptide according to the laboratory beyond-use protocol.
Research designs sometimes evaluate thymosin alpha-1 alongside antivirals, checkpoint-oriented oncology regimens, or other immune modulators when the question is host-response augmentation. It is mechanistically distinct from tissue-repair peptides such as TB-500, so combinations are usually immunology-driven rather than recovery-stack driven.
The questions people actually search for, answered plainly.
Many clinical and translational papers reference about 1.6 mg subcutaneously twice weekly for thymalfasin-style regimens. Other schedules exist; methods sections are the authoritative source.
No. Thymosin alpha-1 is an immunomodulatory thymic peptide. TB-500 relates to thymosin beta-4 actin biology. They are different molecules with different research stories.
Literature describes effects on T-cell maturation, dendritic-cell activation via innate receptors, cytokine balance, and host-defense readiness in suppressed or challenged states.
Research-grade material is RUO and not for human consumption. Pharmaceutical thymalfasin has been used in some countries under local regulatory frameworks, which is a separate product class.
Because multiple studies and reviews examine whether immune reconstitution or immune modulation with Tα1 changes host response in viral disease and sepsis models.
As lyophilized peptide in multi-milligram vials that are reconstituted before in vitro or in vivo experimental use.
No. Many protocols use repeated dosing over weeks because immune endpoints accumulate across a course even when plasma residence time per dose is short.
Primary literature on Thymosin Alpha-1. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides